Lipikind CV 20 Capsule is a combination pharmaceutical formulation containing Atorvastatin 20 mg and Clopidogrel 75 mg, designed for the management of cardiovascular conditions. Atorvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby contributing to the prevention of atherosclerosis and related cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by selectively and irreversibly blocking the P2Y12 ADP receptor on platelet surfaces, reducing the risk of thrombotic events such as myocardial infarction and stroke. The combination of these agents in Lipikind CV 20 Capsule provides a synergistic approach to cardiovascular risk reduction by addressing both lipid abnormalities and platelet-mediated thrombosis. This medication is indicated for patients with established coronary artery disease, recent acute coronary syndrome, or those at high risk for cardiovascular events who require both lipid-lowering and antiplatelet therapy. Lipikind CV 20 Capsule should be administered under medical supervision, with dosage adjustments based on individual patient response and tolerance. Regular monitoring of lipid profiles, liver function tests, and hematologic parameters is recommended to ensure efficacy and safety during treatment.